HighPoint Advisor Group’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,980
| Closed | -$349K | – | 689 |
|
|
2025
Q4 | $349K | Buy |
1,980
+22
| +1% | +$3.59K | 0.01% | 792 |
|
|
2025
Q3 | $274K | Buy |
1,958
+12
| +0.6% | +$1.62K | 0.01% | 561 |
|
|
2025
Q2 | $244K | Buy |
1,946
+210
| +12% | +$26.2K | 0.01% | 591 |
|
|
2025
Q1 | $209K | Sell |
1,736
-198
| -10% | -$28.3K | 0.01% | 612 |
|
|
2024
Q4 | $270K | Buy |
1,934
+381
| +25% | +$64.3K | 0.01% | 547 |
|
|
2024
Q3 | $270K | Sell |
1,553
-346
| -18% | -$72.4K | 0.02% | 522 |
|
|
2024
Q2 | $402K | Sell |
1,899
-8
| -0.4% | -$1.74K | 0.02% | 401 |
|
|
2024
Q1 | $430K | Sell |
1,907
-10
| -0.5% | -$2.34K | 0.03% | 387 |
|
|
2023
Q4 | $415K | Buy |
+1,917
| New | +$471K | 0.03% | 399 |
|
|
2021
Q3 | $348K | Buy |
1,228
+65
| +6% | +$21.3K | 0.03% | 372 |
|
|
2021
Q2 | $403K | Buy |
1,163
+28
| +2% | +$8.48K | 0.04% | 341 |
|
|
2021
Q1 | $304K | Sell |
1,135
-12
| -1% | -$3.24K | 0.04% | 367 |
|
|
2020
Q4 | $309K | Buy |
1,147
+99
| +9% | +$25.5K | 0.04% | 345 |
|
|
2020
Q3 | $345K | Buy |
1,048
+114
| +12% | +$31.8K | 0.06% | 247 |
|
|
2020
Q2 | $247K | Buy |
934
+38
| +4% | +$11.4K | 0.05% | 276 |
|
|
2020
Q1 | $266K | Buy |
896
+27
| +3% | +$8.19K | 0.06% | 234 |
|
|
2019
Q4 | $249K | Buy |
869
+58
| +7% | +$16.1K | 0.05% | 295 |
|
|
2019
Q3 | $237K | Sell |
811
-34
| -4% | -$7.92K | 0.05% | 288 |
|
|
2019
Q2 | $196K | Sell |
845
-73
| -8% | -$16.9K | 0.05% | 310 |
|
|
2019
Q1 | $210K | Sell |
918
-2,217
| -71% | -$698K | 0.05% | 303 |
|
|
2018
Q4 | $1.04M | Buy |
3,135
+272
| +10% | +$86.8K | 0.28% | 83 |
|
|
2018
Q3 | $903K | Buy |
2,863
+2,275
| +387% | +$783K | 0.25% | 96 |
|
|
2018
Q2 | $202K | Sell |
588
-200
| -25% | -$56.2K | 0.05% | 314 |
|
|
2018
Q1 | $239K | Sell |
788
-36
| -4% | -$11.2K | 0.07% | 275 |
|
|
2017
Q4 | $261K | Buy |
824
+20
| +2% | +$6.42K | 0.07% | 243 |
|
|
2017
Q3 | $249K | Buy |
804
+1
| +0.1% | +$296 | 0.08% | 233 |
|
|
2017
Q2 | $231K | Hold |
803
| – | – | 0.07% | 243 |
|
|
2017
Q1 | $231K | Sell |
803
-80
| -9% | -$22.6K | 0.07% | 243 |
|
|
2016
Q4 | $259K | Buy |
+883
| New | +$262K | 0.08% | 235 |
|
|
2016
Q3 | – | Sell |
-801
| Closed | -$252K | – | 288 |
|
|
2016
Q2 | $252K | Buy |
+801
| New | +$211K | 0.09% | 228 |
|
|
2016
Q1 | – | Sell |
-1,217
| Closed | -$327K | – | 228 |
|
|
2015
Q4 | $327K | Buy |
1,217
+200
| +20% | +$57.5K | 0.22% | 135 |
|
|
2015
Q3 | $297K | Buy |
+1,017
| New | +$336K | 0.33% | 105 |
|
Other funds holding BIIB
HighPoint Advisor Group's BIIB Position: Q1 2026 in Review
HighPoint Advisor Group sold out of Biogen (BIIB) in Q1 2026, closing a stake of 1,980 shares — an estimated $349K sold.
HighPoint Advisor Group first reported a position in BIIB in Q3 2015 and held it in 32 quarters. The position peaked at $1.04M in Q4 2018. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- HighPoint Advisor Group reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
- HighPoint Advisor Group sold 1,980 Biogen shares in Q1 2026, an estimated $349K.
- HighPoint Advisor Group first reported a position in Biogen in Q3 2015 and held it in 32 quarters.
- HighPoint Advisor Group's Biogen position peaked at $1.04M in Q4 2018.
- 1,009 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on HighPoint Advisor Group's 13F filing for Q1 2026, filed 14 May 2026.